
Results
2
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
2 companies
argenx
Market Cap: €44.2b
A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
ARGX
€722.40
7D
1.9%
1Y
16.7%
UCB
Market Cap: €52.5b
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
UCB
€276.10
7D
-1.2%
1Y
51.9%